Abstract
Antiangiogenic agents appear as major therapeutic options in renal, colorectal and breast cancer. Their part in thoracic oncology is still limited today except for bevacizumab. We review the current limits of antiangiogenic agents in terms of efficacy, activity, tolerance and therapeutic strategies. Problems about predictive biomarkers and cost-effectiveness of antiangiogenic agents in thoracic oncology are also mentioned.
MeSH terms
-
Age Factors
-
Angiogenesis Inhibitors / adverse effects
-
Angiogenesis Inhibitors / economics
-
Angiogenesis Inhibitors / therapeutic use*
-
Antibodies, Monoclonal, Humanized / adverse effects
-
Antibodies, Monoclonal, Humanized / economics
-
Antibodies, Monoclonal, Humanized / therapeutic use
-
Bevacizumab
-
Biomarkers
-
Carcinoma, Non-Small-Cell Lung / blood supply*
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Humans
-
Lung Neoplasms / blood supply*
-
Lung Neoplasms / drug therapy*
-
Vascular Endothelial Growth Factor A / physiology
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal, Humanized
-
Biomarkers
-
Vascular Endothelial Growth Factor A
-
Bevacizumab